SCHEDULE: Beryl Capital Management Discloses 9.7% Stake in Enzo Biochem Inc.

Beryl Capital Management and its affiliates have disclosed a significant beneficial ownership stake of 9.7% in Enzo Biochem Inc., totaling 5,069,789 shares of common stock.

Summary

• Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin have filed a Schedule 13G, disclosing their beneficial ownership in Enzo Biochem Inc.
• Beryl Capital Management LLC, Beryl Capital Management LP, and David A. Witkin each beneficially own 5,069,789 shares of Enzo Biochem Inc. Common Stock, representing 9.7% of the class.
• Beryl Capital Partners II LP beneficially owns 4,088,352 shares, which constitutes 7.8% of the class.
• The percentage of ownership is calculated based on 52,432,129 shares of Common Stock outstanding as of June 19, 2025, as disclosed in Enzo Biochem Inc.'s Form 8-K filed on June 24, 2025.
• All reporting persons hold shared voting and shared dispositive power over their respective reported shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure, the acquisition of a significant stake by an investment firm generally implies a positive outlook from the investor's perspective, suggesting perceived value in the company. The disclaimer of control-influencing intent also reduces immediate negative implications of potential activism.

Positives

• A significant institutional investment firm, Beryl Capital Management, has taken a substantial stake in Enzo Biochem Inc., potentially signaling confidence in the company's long-term prospects.
• The filing indicates that the shares were acquired in the ordinary course of business, suggesting a strategic investment rather than an immediate activist intent to change control, which can provide stability.

Negatives

• No specific negative financial or operational details are disclosed in this beneficial ownership filing.

Risks

• While the filing disclaims intent to change control, a large beneficial ownership stake by an investment firm could still lead to increased shareholder activism or pressure on management in the future, potentially impacting strategic direction.
• The concentration of a significant portion of the company's stock in the hands of a few entities could influence liquidity or trading dynamics.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Enzo Biochem Inc.'s future financial performance or strategic direction.

Industry Context

The disclosure of a significant stake by an investment firm like Beryl Capital Management in a biotechnology company such as Enzo Biochem Inc. is a common occurrence in the financial markets. Such filings often indicate that institutional investors see value or potential in the company's sector or specific business model, aligning with broader trends of capital allocation towards innovative healthcare and life sciences companies. This type of investment can signal market confidence or a belief in the company's strategic direction within the competitive biotechnology landscape.

Related Party Transactions

• A Joint Filing Agreement was executed on July 1, 2025, among Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin, to jointly file statements on Schedule 13D or 13G and Forms 3, 4, or 5. Beryl Capital Management LLC is appointed as their agent and attorney-in-fact for this purpose.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and attracting further institutional interest. It could also lead to increased scrutiny of management's performance.
• Management: Management may face increased engagement or potential pressure from a large shareholder, even if the filing disclaims control intent, especially concerning strategic decisions or capital allocation.
• Employees, Customers, Suppliers, Creditors: No direct immediate impact is indicated by this filing, as it primarily concerns ownership structure.

Key Dates

Keywords

Enzo Biochem Inc., Beryl Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Shareholder Stake, Investment Management, Biotechnology, Healthcare